<DOC>
	<DOC>NCT00302653</DOC>
	<brief_summary>The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.</brief_summary>
	<brief_title>Rasburicase in Tumor Lysis Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Tumor Lysis Syndrome</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>List of inclusion Criteria: Acute hyperuricemia patients(uric acid&gt;8.0 mg/dl) before/during chemotherapy for hematologic malignancies. List of exclusion Criteria: Hypersensitivity to uricases or any of the excipients. Known history of hemolytic anemia (G6PD deficiency). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>